



The apoA-I companY

Press release

## **ABIONYX Pharma announces approval of all resolutions put to the vote at its Combined General Meeting**

**Toulouse, FRANCE, Lakeland MI, USA, June 27<sup>th</sup>, 2025, 6:30 p.m. CEST - ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible),** a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were approved.

ABIONYX Pharma would like to thank all shareholders present, represented or having voted by post for their commitment and support at this General Meeting.

The minutes of the General Meeting and the results of the votes by resolution are available on the Company's website in the [Shareholder Meeting](#) section.

### **About ABIONYX Pharma**

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.

### **Contacts**

#### **NewCap**

Investor relations  
Louis-Victor Delouvrier  
Théo Martin  
[abionyx@newcap.eu](mailto:abionyx@newcap.eu)  
+33 (0)1 44 71 98 53

#### **NewCap**

Media relations  
Arthur Rouillé  
[abionyx@newcap.eu](mailto:abionyx@newcap.eu)  
+33 (0)1 44 71 94 98